QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nvidia-amd-alzamend-neuro-palo-alto-networks-tesla-why-these-5-stocks-are-on-investors-radars-today

On Monday, major U.S. indices closed in positive territory. The Dow Jones Industrial Average rose 0.6% to finish at 40,896.53.

 alzamend-neuro-stock-jumps-after-post-traumatic-stress-disorder-study-pact-details

Alzamend Neuro stock rises after partnering with Massachusetts General Hospital for a Phase 2 trial of AL001 to treat PTSD. The...

Core News & Articles

ALZN: 248% | Alzamend Neuro Partners With Massachusetts General Hospital For First-of-Its-Kind Phase II Study Of AL001 For PTSD...

 alzamend-neuro-partners-with-massachusetts-general-hospital-for-first-of-its-kind-phase-ii-study-of-al001-for-ptsd-treatment

Harvard Associate Professor Dr. Ovidiu Andronesi To Lead Study Comparing AL001 To Marketed Lithium Carbonate In Human Brain

 alzamend-neuro-partners-with-massachusetts-general-hospital-for-a-phase-ii-clinical-trial-of-al001-a-nextgeneration-lithium-therapeutic-drug-candidate

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the studyHead-to-he...

 alzamend-neuro-regains-compliance-with-nasdaqs-minimum-bid-price-requirement

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel...

 alzamend-neuro-announces-1-for-10-reverse-stock-split-beginning-with-the-opening-of-trading-on-july-16-2024

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend" or the "Company"), a clinical-stage biopharmaceutical company fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION